Navigation Links
Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality
Date:5/18/2009

HOUSTON, May 18 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that Bryan D. Olin, Ph.D., joined Cyberonics as Vice President, Quality, effective on May 18, 2009. Dr. Olin will lead all of the company's quality programs.

Dr. Olin joins Cyberonics from Zeltiq Aesthetics, an aesthetics device firm in California, where he served as Senior Director, Quality Assurance, since October 2007. Prior to Zeltiq, Dr. Olin was employed as Executive Director, Failure Analysis, Product Quality Services and Product Safety with Cordis Corporation, a Johnson & Johnson company. Dr. Olin spent five years with another Johnson & Johnson company, LifeScan, as the Manager, Statistical Engineering; Senior Program Manager, QA; Director, Complaint Handling and QA Laboratories; and Director, Clinical Biometrics and Complaint Management. Dr. Olin began his business career as a Statistician for Procter & Gamble, providing statistical support to a diverse set of internal clients in R&D and manufacturing.

"Bryan brings substantial expertise in quality management that will be helpful in all aspects of our regulated business, including manufacturing and product development," said Dan Moore, Cyberonics' President and Chief Executive Officer. "He has extensive experience with regulatory inspections and submissions, complaint handling, CAPAs and clinical study design. We are pleased to have Bryan joining our team to lead the global quality system and programs."

Dr. Olin received a B.S. in Mathematics from the University of Kansas. He was awarded a Masters of Science and his Ph.D. in Statistics from Iowa State University. Dr. Olin served as an Adjunct Assistant Professor of Industrial Pharmacy at the University of Cincinnati for three years.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (NASDAQ: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.

Contact information

    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd.
    Houston, TX 77058
    Main:  (281) 228-7262
    Fax:  (281) 218-9332
    ir@cyberonics.com


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
2. Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter
3. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results
4. Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development
5. Cyberonics to Present at Piper Jaffray 20th Annual Health Care Conference
6. Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
7. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
8. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
9. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike
10. Cyberonics to Present at UBS Global Life Sciences Conference
11. Cyberonics to Present at Canaccord Adams 28th Annual Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software ... and employees that are both engaging and easy to use. Coming off the ... software company revealed today its plans to roll out new AI-powered self-service enhancements ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... Dallas, TX (PRWEB) , ... December 08, 2016 , ... ... to continue to be a convenient service for Texas, they are expanding their presence ... will involve a hiring spree that will bring new jobs to the Dallas and ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients ... With this in mind, SIGVARIS has created a new line of anti-embolism stockings ... rest and provide the benefits of graduated compression when transitioning from recovery to ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
(Date:12/8/2016)... 2016 Australia Glaucoma Surgery Devices Market ... report, "Australia Glaucoma Surgery Devices Market Outlook to ... Glaucoma Surgery Devices market. The report provides value, ... and average prices (USD) within market segement - ... company shares and distribution shares data for each ...
(Date:12/8/2016)... , Dec. 8, 2016 KEY FINDINGS ... to grow in 2017-2023. Various reasons for growth of ... population, higher incidences of chronic diseases, high recovery cost ... aid services. Medical lifting sling refers to an ... limited mobility. These slings connect to the lift and ...
Breaking Medicine Technology: